SCHEMBL6740527

SCHEMBL6740527

COc1ccc(-n2c(-c3cc(F)c(S(C)(=O)=O)cc3F)csc2=O)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 14/20 0.43
PTGS1 P23219 5/20 0.39
HPGD P15428 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 3/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
HSD17B10 Q99714 1/20 0.35
THRB P10828 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737078 0.92 PTGS2 (0.36) PTGS2PTGS1ALDH1A1MAPTLMNA
SCHEMBL6729227 0.91 PTGS2 (0.45) PTGS2PTGS1HPGDALDH1A1CYP1A2
SCHEMBL6736524 0.89 SCN9A (0.33) PTGS2PTGS1MEN1KMT2AHTT
SCHEMBL6734589 0.87 PTGS2 (0.40) PTGS2PTGS1HPGDALDH1A1MAPT
SCHEMBL6722867 0.86 PTGS2 (0.46) PTGS2PTGS1HPGDALDH1A1CYP1A2
SCHEMBL6732679 0.85 PTGS2 (0.40) PTGS2PTGS1
SCHEMBL6734751 0.84 CCR2 (0.36) PTGS2PTGS1ALDH1A1MAPTMEN1
SCHEMBL6732370 0.83 PTGS2 (0.37) PTGS2PTGS1ALDH1A1MAPTLMNA
SCHEMBL6740069 0.83 PTGS2 (0.41) PTGS2PTGS1
SCHEMBL6731937 0.82 ALDH1A1 (0.39) PTGS2PTGS1ALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885HPGD 917/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885HPGD 917/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 PTGS2 10/4885PTGS1 4/4885HPGD 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.